✦ LIBER ✦

Risk of pruritus in cancer patients treated with inhibitors of the mammalian target of rapamycin, everolimus and temsirolimus: A systematic review of the literature and metaanalysis

Book ID: 123234883
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 44 KB
Volume: 68
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2012.12.256

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of pruritus in cancer patients trea

Risk of pruritus in cancer patients treated with cetuximab: A systematic review of the literature and metaanalysis

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

The risk of skin rash and stomatitis wit

The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis

✍ Cristina Gomez-Fernandez; Benjamin C. Garden; Shenwong Wu; Darren R. Feldman; Ma 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 602 KB

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

O-99 The mTOR (mammalian target of rapam

O-99 The mTOR (mammalian target of rapamycin) inhibitor RAD001 (Everolimus) is safe and reduces proliferation in postmenopausal women with breast cancer

✍ E.J. Macaskill; J.M.S. Bartlett; L. Renshaw; D. Faratian; S. White; F.M. Campbel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Phase 1 and pharmacokinetic study of eve

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

✍ Suresh S. Ramalingam; R. Donald Harvey; Nabil Saba; Taofeek K. Owonikoko; John K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

Risk of Rash Associated With Lenalidomid

Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis

✍ Nardone, Beatrice; Wu, Shenhong; Garden, Benjamin C.; West, Dennis P.; Reich, Li 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 657 KB